📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-28 17:42
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
₹1.30 Dividend and MD Transition Approved; 31% Institutional Dissent on Advisory Fees
Sumitomo Chemical India shareholders approved all 10 resolutions at the AGM held on July 27, 2026, including a dividend of ₹1.30 per share. A major leadership transition was ratified, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah. Notably, Resolution 8 regarding advisory fees for the outgoing MD faced 31.04% dissent from institutional investors, though it passed. Material related party transactions with the Japanese parent for FY27 were also cleared.
Confidence: HIGH
What changedFormal approval of the FY26 dividend and the transition of the Managing Director role from Mr. Chetan Shah to Dr. Suresh Ramachandran.
Why it mattersEnsures leadership continuity and maintains the strategic and operational link with the Japanese parent company through approved related party transactions for proprietary products.
Dividend per share: ₹1.30Institutional Dissent (Res 8): 31.04%MD Promotion Date: 1st September 2026Total Shareholders: 112,060Dividend vs TTM EPS: ~11.9%
📅 Short termNeutral; the dividend payout and management transition were expected and are likely already priced in by the market.
📈 Long termThe new MD's ability to leverage the parent company's R&D and execute the specialty molecule expansion will be critical for sustaining the 19-20% growth target.
⚠ Risk flags
- Significant institutional dissent on advisory fees for the outgoing MD
- High dependence on parent company for proprietary product pipeline
Key Highlights
Approved a dividend of ₹1.30 per equity share (13% of face value) for FY26.
Confirmed Dr. Suresh Ramachandran's promotion to Managing Director effective September 1, 2026.
Resolution 8 (Advisory fees for outgoing MD) saw 1,64,79,392 institutional votes against, representing 31.04% of institutional votes polled.
Material Related Party Transactions with parent Sumitomo Chemical Company, Ltd approved for FY27.
Total of 112,060 shareholders were on record for the meeting held on July 27, 2026.
👀 What to Watch
Monitor the leadership transition on September 1, 2026, and track the execution of the SCI 2.0 initiative, specifically the ₹120 Cr capex aimed at adding ₹200-250 Cr in annual revenue.
Sumitomo Chemical Q1 FY27: PAT up 20% to ₹215 Cr; Major Board Reconstitution Announced
Sumitomo Chemical India (SCIL) reported a resilient Q1 FY27 with revenue growing 1% YoY to ₹1,063 crore, despite a 40% rainfall deficit impacting domestic demand. PAT rose 20% to ₹215 crore, significantly aided by a ₹26.9 crore exceptional insurance claim and a 26% surge in export revenue. EBITDA margins expanded by 120 bps to 21.9% due to disciplined pricing and a favorable product mix. The company also announced a major leadership transition effective September 1, 2026, including the appointment of a new Managing Director.
Confidence: HIGH
What changedThe company has successfully offset domestic monsoon-related weakness through export growth and margin expansion, while formalizing a major management succession plan.
Why it mattersThe results demonstrate strong operating leverage and the benefit of parent Sumitomo Chemical's global supply chain. The leadership transition provides clarity on long-term governance.
Q1 Revenue: ₹1,063 crQ1 PAT: ₹215 crEBITDA Margin: 21.9%Export Growth: 26% YoYExceptional Insurance Gain: ₹26.9 crRainfall Deficit (June-end): 40%
📅 Short termThe stock may see positive sentiment due to margin resilience and the one-time insurance gain, though domestic volume growth remains a monitorable due to early-season monsoon delays.
📈 Long termThe 'SCI 2.0' strategy focusing on specialty molecules and the integration with the Japanese parent's R&D pipeline supports a structural growth story in the agrochemical space.
⚠ Risk flags
- High channel inventory in the domestic market
- Dependency on monsoon distribution for kharif and rabi seasons
- Management transition execution risk
Key Highlights
Revenue reached ₹1,063 crore, up 1% YoY despite a ~20% decline in early-season kharif sowing area.
Exports grew 26% YoY, now contributing 16% of total revenues compared to previous periods.
EBITDA margin expanded to 21.9% from 20.7% YoY, driven by a 111 bps improvement in gross margins.
Reported PAT of ₹215 crore includes a ₹26.9 crore insurance claim for a FY23 fire incident at the Bhavnagar plant.
Dr. Suresh Ramachandran appointed as Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah.
👀 What to Watch
Watch for the recovery in domestic volumes in Q2 as monsoon progress improved in July, and monitor the execution of the leadership transition in September. The launch of new products Topgrain and Helibax in Q2 FY27 will be key for growth momentum.
₹1.30 Dividend Approved; Dr. Suresh Ramachandran to take over as MD from Sept 2026
Sumitomo Chemical India Limited (SCIL) concluded its 26th AGM on July 27, 2026, approving a dividend of ₹1.30 per equity share for FY26. A major leadership transition was finalized, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah, who will transition to a Non-Executive Director role. Shareholders also approved material related party transactions with the Japanese parent company for FY27, ensuring continued access to proprietary chemistry and products.
Confidence: HIGH
What changedThe company has formalized its leadership succession plan and confirmed the dividend payout for the previous financial year.
Why it mattersLeadership continuity is vital for SCIL as it leverages its Japanese parent's R&D to launch high-margin specialty products; the MD transition marks a new phase in the company's growth strategy.
Dividend per share: ₹1.30Estimated Dividend Payout: ₹64.88 CrDividend vs TTM PAT: ~11.9%MD Transition Date: 1st September 2026AGM Attendance: 65 members
📅 Short termThe stock is likely to remain stable as the dividend and management changes were largely expected and follow standard corporate governance procedures.
📈 Long termThe transition to Dr. Ramachandran's leadership will be key to achieving the targeted 19-20% growth rate and successfully integrating the ₹120 Cr capex for new products.
⚠ Risk flags
- Related-party transactions with parent company
- Execution risk during leadership transition
Key Highlights
Dividend of ₹1.30 per equity share declared for the financial year ended March 31, 2026.
Dr. Suresh Ramachandran promoted from Deputy MD to Managing Director effective September 1, 2026.
Mr. Chetan Shah transitions from Managing Director to Non-Executive Director starting September 1, 2026.
Approval granted for material related party transactions with parent Sumitomo Chemical Company, Ltd for FY 2026-27.
Reappointment of Mr. N. Sivaraman as Independent Director for a second three-year term.
👀 What to Watch
Investors should monitor the leadership transition in September 2026 and track the execution of the 'SCI 2.0' initiative under the new Managing Director.
Sumitomo Chemical Q1 Net Profit Rises 20% to ₹216.5 Cr; Revenue Flat at ₹1,054 Cr
Sumitomo Chemical India reported a 20.4% YoY increase in standalone net profit to ₹216.53 Cr for the quarter ended June 30, 2026, despite revenue remaining nearly stagnant at ₹1,054.08 Cr. The bottom line was supported by an exceptional gain of ₹26.90 Cr from an insurance claim related to a 2022-23 fire incident. Operating efficiency improved as total expenses declined slightly by 1% YoY to ₹836.77 Cr. The company's performance remains highly seasonal, with this quarter contributing approximately 32.6% of the previous year's total revenue.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, showing a significant recovery in profitability and margin expansion despite a flat top-line, aided by a one-time insurance settlement.
Why it mattersThe results demonstrate strong cost management and the ability to maintain profitability in a challenging agrochemical environment. The settlement of the Bhavnagar fire insurance claim removes a long-standing financial uncertainty.
Standalone Revenue (Q1): ₹1,054.08 CrStandalone Net Profit (Q1): ₹216.53 CrExceptional Insurance Gain: ₹26.90 CrQ1 Revenue vs TTM Revenue: 32.6%EPS (Q1): ₹4.34
📅 Short termThe stock may see positive sentiment due to the 20% profit growth and margin improvement, although the flat revenue growth reflects ongoing industry-wide volume/pricing pressures.
📈 Long termLong-term growth is tied to the parent company's (SCCL Japan) technology transfers and the successful ramp-up of specialty high-margin molecules which are less sensitive to generic pricing cycles.
⚠ Risk flags
- Regulatory risk regarding Glyphosate usage restrictions
- High dependency on monsoon and climatic conditions
- Loss-making subsidiaries (Barrix Agro Sciences)
Key Highlights
Standalone Net Profit increased to ₹216.53 Cr from ₹179.81 Cr in the same quarter last year, a 20.4% growth.
Revenue from operations stood at ₹1,054.08 Cr, showing marginal growth of 0.6% over June 2025's ₹1,048.07 Cr.
Exceptional item of ₹26.90 Cr recognized as an insurance claim for business interruption at the Bhavnagar plant.
Earnings Per Share (EPS) improved to ₹4.34 for the quarter compared to ₹3.60 in the year-ago period.
Subsidiaries contributed a combined net loss of ₹1.91 Cr, slightly dragging consolidated performance.
👀 What to Watch
Monitor the execution of the 'SCI 2.0' initiative and the revenue contribution from the 5 new products launched via the ₹120 Cr capex. Investors should also track the Delhi High Court's final decision on Glyphosate restrictions, as it remains a key product for the company.
Q1 PAT Rises 20.4% to ₹216.5 Cr; Revenue Flat at ₹1,054 Cr
Sumitomo Chemical India reported a steady Q1 FY27 with revenue from operations remaining nearly flat at ₹1,054.1 Cr, a 0.6% YoY increase. However, Net Profit grew significantly by 20.4% YoY to ₹216.5 Cr, driven by a ₹26.9 Cr exceptional insurance claim and a 1% reduction in total expenses. The company's EPS improved to ₹4.34 from ₹3.60 in the year-ago period. While the top line was stagnant, margin expansion was evident as the company managed costs effectively despite a seasonal business environment.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, highlighting a significant jump in profitability despite stagnant revenue growth.
Why it mattersThe results demonstrate strong cost control and the realization of one-off insurance gains, which bolstered the bottom line. It shows resilience in a seasonal industry where performance is heavily dependent on monsoon conditions.
Revenue (Q1 FY27): ₹1,054.08 CrNet Profit (Q1 FY27): ₹216.53 CrExceptional Gain: ₹26.90 CrQ1 Revenue vs TTM Revenue: 32.6%YoY PAT Growth: 20.4%
📅 Short termThe stock may react positively to the strong profit growth and margin improvement, although the flat revenue growth might temper extreme bullishness.
📈 Long termThe company's structural advantage through its Japanese parent (SCCL) and shift toward high-margin specialty molecules under SCI 2.0 remains a key long-term value driver.
⚠ Risk flags
- Seasonality and monsoon dependency
- Regulatory risk regarding Glyphosate usage restrictions
- High-cost inventory carryover risks
Key Highlights
Revenue from operations stood at ₹1,054.08 Cr, showing marginal growth of 0.6% over ₹1,048.07 Cr in Q1 FY26.
Net Profit increased by 20.4% YoY to ₹216.53 Cr, compared to ₹179.81 Cr in the previous year's corresponding quarter.
Exceptional gain of ₹26.90 Cr recorded during the quarter from an insurance claim for business interruption at the Bhavnagar plant.
Total expenses decreased to ₹836.77 Cr from ₹844.80 Cr YoY, reflecting improved operational efficiency.
Earnings Per Share (EPS) for the quarter rose to ₹4.34 from ₹3.60 YoY.
👀 What to Watch
Watch for the execution of the 'SCI 2.0' initiative and the revenue contribution from the 5 new products launched via the ₹120 Cr capex. Investors should also monitor the legal outcome regarding Glyphosate usage restrictions which could impact future volumes.
Sumitomo Chemical India Proposes ₹1,623.5 Cr Related Party Transactions and New MD Appointment
Sumitomo Chemical India has issued a notice for its 26th AGM on July 27, 2026, featuring several key resolutions. Most significant is the proposal for material related party transactions (RPT) with its Japanese parent company totaling ₹1,623.5 cr for FY27, representing approximately 50% of its TTM revenue. The board also seeks to promote Dr. Suresh Ramachandran to Managing Director effective September 1, 2026. Additionally, shareholders will vote on a ₹3 cr advisory fee cap for Non-Executive Director Mr. Chetan Shah and a dividend declaration for FY26.
Confidence: HIGH
What changedThe company is formalizing its leadership transition with a new Managing Director and setting the financial limits for its critical supply-chain relationship with its Japanese parent for the upcoming fiscal year.
Why it mattersThe high volume of related party transactions (50% of revenue) underscores the company's reliance on its parent for proprietary products and raw materials, which is central to its 'SCI 2.0' growth strategy.
Proposed RPT with Parent (FY27): ₹1,623.5 crRPT vs TTM Revenue: ~50.3%Advisory Fee Cap (Chetan Shah): ₹3 crAGM Date: July 27, 2026Cost Auditor Remuneration: ₹5.5 lakh
📅 Short termThe announcement is procedural and likely to have a neutral impact on the stock price in the coming weeks as it aligns with standard annual corporate governance cycles.
📈 Long termThe promotion of Dr. Ramachandran to MD ensures leadership continuity as the company executes its ₹120 cr capex plan and targets 19-20% growth through specialty molecules.
⚠ Risk flags
- High related-party transaction concentration (50% of revenue)
- Significant advisory fees for a non-executive director exceeding 50% of total non-executive remuneration
Key Highlights
Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, total ₹1,623.5 cr for FY27
Dr. Suresh Ramachandran to be promoted to Managing Director from September 1, 2026, until May 31, 2028
Proposed RPT value of ₹1,623.5 cr represents ~50.3% of the company's TTM revenue of ₹3,230 cr
Advisory fees and commission for Mr. Chetan Shah capped at ₹30 million (₹3 cr) for the period Sept 2026 to Aug 2027
Appointment of two Independent Directors, Mr. N Sivaraman (3 years) and Mr. Anand Mohan Tiwari (2 years)
👀 What to Watch
Investors should monitor the AGM voting results on July 27, 2026, specifically regarding the high-value related party transactions and the remuneration structure for non-executive directors.
Sumitomo Chemical to Seek Approval for ₹1,623.5 Cr Related Party Transactions and New MD
Sumitomo Chemical India (SUMICHEM) has issued a notice for its 26th AGM on July 27, 2026. Key resolutions include the promotion of Dr. Suresh Ramachandran to Managing Director and the approval of material Related Party Transactions (RPT) with its Japanese parent totaling ₹16,235 million for FY27. This RPT volume is significant, representing approximately 50.3% of the company's TTM revenue. Shareholders will also vote on a ₹30 million advisory fee for Non-Executive Director Mr. Chetan Shah and the appointment of new independent directors.
Confidence: HIGH
What changedThe company is formalizing a leadership transition with a new Managing Director and setting the financial framework for its extensive supply chain relationship with its Japanese parent for the next fiscal year.
Why it mattersThe high volume of Related Party Transactions (over 50% of revenue) highlights the company's deep integration with its parent's global supply chain, which is a key competitive moat but also a concentration risk.
Proposed RPT with Parent (FY27): ₹16,235 millionRPT vs TTM Revenue: ~50.3%Advisory Fee Cap (Mr. Chetan Shah): ₹30 millionAGM Date: July 27, 2026TTM Revenue: ₹3,230 Cr
📅 Short termThe announcement is procedural; the stock is unlikely to react significantly until the dividend amount is finalized and voting results are out.
📈 Long termLeadership continuity under the new MD and the sustained relationship with the Japanese parent are critical for executing the ₹120 Cr capex plan and launching 5 new products.
⚠ Risk flags
- High concentration of Related Party Transactions (50%+ of revenue)
- Significant advisory payments to a Non-Executive Director exceeding 50% of total NED remuneration
Key Highlights
Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, totaling ₹16,235 million for FY27
Promotion of Dr. Suresh Ramachandran to Managing Director effective September 1, 2026, until May 31, 2028
Proposed advisory fees and commission for Mr. Chetan Shah capped at ₹30 million for the period Sept 2026 to Aug 2027
Appointment of Mr. Anand Mohan Tiwari as an Independent Director for a 2-year term starting August 31, 2026
Ratification of Cost Auditor remuneration at ₹550,000 for FY27
👀 What to Watch
Investors should monitor the AGM voting results, specifically the approval of the high-value Related Party Transactions and the leadership transition, to ensure alignment with the company's 'SCI 2.0' growth strategy.
Sumitomo Chemical to Approve Rs 1,623.5 Cr Related Party Transactions and New MD at July 27 AGM
Sumitomo Chemical India has scheduled its 26th AGM for July 27, 2026, to vote on several key resolutions including a massive Related Party Transaction (RPT) mandate. The company is seeking approval for transactions with its Japanese parent totaling Rs 1,623.5 Cr for FY 2026-27, which represents approximately 50.3% of its TTM revenue. Leadership changes are also on the agenda, with the proposed promotion of Dr. Suresh Ramachandran to Managing Director and the appointment of Mr. Chetan Shah as a Non-Executive Director with an advisory fee cap of Rs 3 Cr. These moves formalize the company's deep operational integration with its parent and its long-term leadership structure.
Confidence: HIGH
What changedThe company is initiating a leadership transition with a new Managing Director and setting formal financial limits for its extensive supply chain and service dependencies on its Japanese parent company.
Why it mattersThe RPT volume (50% of revenue) highlights the company's core strategy of leveraging its parent's proprietary chemistry; leadership continuity is vital for the 'SCI 2.0' initiative and the planned Rs 120 Cr capex execution.
RPT with Parent (FY27): Rs 1,623.5 CrRPT vs TTM Revenue: 50.3%Advisory Fee Cap (Mr. Chetan Shah): Rs 3 CrAGM Date: July 27, 2026Cost Auditor Fee: Rs 5.5 Lakhs
📅 Short termThe announcement is procedural and unlikely to trigger immediate price volatility; focus will remain on the dividend declaration and the upcoming AGM commentary.
📈 Long termThe leadership transition and sustained RPT framework suggest a stable, long-term reliance on the Japanese parent's technology and product pipeline, which is central to the company's high-margin specialty focus.
⚠ Risk flags
- High concentration of Related Party Transactions (50% of revenue)
- Potential minority shareholder scrutiny over Rs 3 Cr advisory fees for a Non-Executive Director
Key Highlights
Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, total Rs 1,623.5 Cr for FY 2026-27.
Promotion of Dr. Suresh Ramachandran to Managing Director effective September 1, 2026, through May 31, 2028.
Approval sought for advisory fees and commission for Mr. Chetan Shah capped at Rs 30 million (Rs 3 Cr).
Reappointment of Mr. N Sivaraman as Independent Director for a second term of 3 years starting September 2026.
Ratification of Cost Auditor remuneration fixed at Rs 5.5 Lakhs for the financial year 2026-27.
👀 What to Watch
Investors should monitor the AGM voting results, specifically the approval of the large RPT limits and the remuneration structure for the Non-Executive Director, to ensure alignment with minority shareholder interests.
Sumitomo Chemical India Sets July 17 as Record Date for ₹1.30 Dividend
Sumitomo Chemical India Limited has fixed July 17, 2026, as the record date to determine shareholder eligibility for a dividend of ₹1.30 per equity share for the financial year 2025-26. This announcement follows the board's decision to reward shareholders for the fiscal year's performance. Investors must hold the company's shares in their demat accounts by the record date to qualify for the payout. The notification was issued in compliance with SEBI Listing Obligations and Disclosure Requirements.
Key Highlights
Record date for dividend eligibility is fixed for July 17, 2026.
Dividend amount declared is ₹1.30 per equity share for FY 2025-26.
The announcement is made pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015.
The dividend payout targets shareholders of record for the 2025-26 financial year.
👀 What to Watch
Investors seeking the dividend should ensure they own the stock before the ex-dividend date (typically one trading day before the record date). Existing shareholders should maintain their holdings through the record date to receive the ₹1.30 per share payout.
Sumitomo Chemical India FY26 PAT Rises 7% to ‡543 Cr with Record 20.7% EBITDA Margin
Sumitomo Chemical India reported its highest-ever annual profitability in FY26, with PAT growing 7% to ‡543 crores despite a challenging agrochemical environment. The company achieved record EBITDA margins of 20.7% and Gross Profit margins of 42%, driven by a shift toward branded formulations which now comprise 81% of domestic sales. Management announced a significant leadership transition effective September 2026, with Dr. Suresh Ramachandran elevated to Managing Director. While FY26 revenue grew a modest 3%, the company maintained pricing integrity and saw strong growth in the herbicide segment.
Key Highlights
Achieved record EBITDA margin of 20.7% and Net Profit margin of 16.8% for FY26.
PAT grew 7% YoY to ‡543 crores, with PBT before exceptional items rising over 9%.
Herbicides segment registered 19% full-year growth, including a massive 87% jump in Q4.
Branded formulation share in domestic sales improved to 81% from 79% in the previous year.
Announced leadership transition: Dr. Suresh Ramachandran to succeed Chetan Shah as MD on September 1, 2026.
👀 What to Watch
Investors should view the record margins as a sign of strong pricing power and operational efficiency, though the 'below normal' monsoon forecast for FY27 warrants caution regarding near-term volume growth. The planned management transition appears well-structured, suggesting continuity in the company's specialty-focused strategy.
Sumitomo Chemical India FY26 PAT Up 7% to ₹543 Cr; Announces Leadership Transition
Sumitomo Chemical India (SCIL) reported a resilient performance for FY26 despite industry headwinds, with revenue growing 3% to ₹3,238 crore. The company achieved its highest-ever profitability, with PAT rising 7% to ₹543 crore and net profit margins expanding to 16.8%. A significant management transition was announced, with Dr. Suresh Ramachandran set to take over as Managing Director in September 2026. The company maintains a very strong liquidity position with cash and liquid investments totaling approximately ₹2,113 crore.
Key Highlights
FY26 Revenue grew 3% YoY to ₹3,238 crore, while Q4FY26 revenue remained stable at ₹684 crore.
Annual PAT increased 7% to ₹543 crore, despite a one-time exceptional charge of ₹16.1 crore related to new Labour Codes.
EBITDA margins improved to 20.7% for FY26, driven by a favorable product mix and disciplined pricing actions.
The Herbicides segment showed exceptional momentum, growing 87% YoY in Q4 and 19% for the full year.
Strong balance sheet maintained with cash, cash equivalents, and liquid investments of ~₹2,113 crore as of March 2026.
👀 What to Watch
Investors should take confidence in the company's ability to expand margins and maintain high cash levels during a challenging year for the agrochemical sector. Monitor the leadership transition in September 2026 to ensure strategic continuity.
Sumitomo Chemical India FY26 Net Profit Rises 8% to ₹5,431 Million; Dividend of ₹1.3 Declared
Sumitomo Chemical India reported a steady performance for the fiscal year ended March 31, 2026, with annual revenue growing 3% to ₹31,857.62 million. Net profit for the full year increased by 8.2% to ₹5,431.39 million, even after accounting for a one-time exceptional charge of ₹151.86 million related to new labor code regulations. The company's cash and cash equivalents nearly doubled to ₹675.29 million, indicating a strong liquidity position. The Board has recommended a dividend of ₹1.3 per share, maintaining its commitment to shareholder returns.
Key Highlights
Annual Revenue from operations increased to ₹31,857.62 million in FY26 from ₹30,903.69 million in FY25.
Net Profit for the full year rose to ₹5,431.39 million compared to ₹5,019.48 million in the previous year.
The Board recommended a dividend of ₹1.3 per equity share (13% of face value) for FY 2025-26.
Standalone Earnings Per Share (EPS) improved to ₹10.88 from ₹10.06 year-on-year.
An exceptional item of ₹151.86 million was recognized due to the financial impact of new Government Labour Codes.
👀 What to Watch
Investors may find the steady growth and consistent dividend payout attractive, especially given the seasonal nature of the agro-chemical industry. It is advisable to monitor the legal proceedings regarding Glyphosate usage restrictions which remain a key product for the company.
Sumitomo Chemical India Announces Board Reappointments and MD Transition to Non-Executive Role
Sumitomo Chemical India has announced a planned leadership transition where current Managing Director Mr. Chetan Shah will move to a Non-Executive Director role starting September 1, 2026. The board has also reappointed Mr. N. Sivaraman as an Independent Director for a second three-year term and appointed Mr. Anand Mohan Tiwari as a new Independent Director for two years. These appointments aim to ensure continuity of expertise while refreshing the board's independent oversight. All appointments are subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
MD Chetan Shah to transition to Non-Executive Non-Independent Director effective September 1, 2026.
Mr. N. Sivaraman reappointed as Independent Director for a 3-year term from 2026 to 2029.
Mr. Anand Mohan Tiwari appointed as Independent Director for a 2-year term starting August 31, 2026.
Mr. N. Sivaraman brings 42 years of finance experience, including past roles as MD & Group CEO at ICRA Limited.
Mr. Anand Mohan Tiwari is a retired IAS officer with over three decades of experience in governance and the chemical sector.
👀 What to Watch
Investors should monitor for the announcement of the new Managing Director successor as Mr. Chetan Shah's executive term ends in August 2026. The moves indicate a structured succession plan which is generally positive for long-term stability.
Sumitomo Chemical India Promotes Dr. Suresh Ramachandran to Managing Director
Sumitomo Chemical India Limited has announced the promotion of Dr. Suresh Ramachandran to the position of Managing Director, effective September 1, 2026. Dr. Ramachandran, currently the Deputy Managing Director, has over 28 years of experience in the crop protection industry and holds a Ph.D. in Entomology. He joined the company in March 2021 as Chief Commercial Officer and has seen a steady rise through the leadership ranks. His appointment, which runs until May 31, 2028, is subject to shareholder approval via a special resolution.
Key Highlights
Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026
Appointment term set from September 1, 2026, until May 31, 2028
Brings over 28 years of industry experience including roles at Dow AgroSciences and Indofil Industries
Joined SUMICHEM in March 2021 and was promoted to Deputy MD in September 2024
Currently serves as Vice Chairman of the Agro Chem Federation of India
👀 What to Watch
Investors should view this internal promotion as a sign of leadership continuity and stability within the company. No immediate action is required as the transition is scheduled for late 2026.
Sumitomo Chemical India Declares Final Dividend of ₹1.30 Per Share for FY 2025-26
Sumitomo Chemical India Limited has recommended a final dividend of ₹1.30 per equity share for the financial year 2025-26. The dividend is declared on a total of 49,91,45,736 equity shares with a face value of ₹10 each. This payout is subject to the approval of shareholders at the upcoming Annual General Meeting. If approved, the dividend will be paid to eligible shareholders on or after August 3, 2026.
Key Highlights
Recommended final dividend of ₹1.30 per equity share for the financial year 2025-26
Dividend applicable to 49,91,45,736 equity shares of ₹10 each
Payment scheduled to be disbursed on or after August 3, 2026, post-AGM approval
Board meeting concluded on May 26, 2026, at 04:46 P.M. to finalize the recommendation
👀 What to Watch
Investors should hold the stock to qualify for the dividend and watch for the announcement of the record date. The payout reflects the company's commitment to returning capital to shareholders.
Sumitomo Chemical FY26 PAT Rises 8.2% to ₹5,431 Million; Declares ₹1.30 Dividend
Sumitomo Chemical India reported a steady performance for the full year ended March 31, 2026, with annual revenue growing 3% to ₹31,857.62 million. Net profit for the year increased by 8.2% to ₹5,431.39 million, despite a one-time exceptional charge of ₹151.86 million related to new labor code regulations. The company maintained a strong balance sheet and recommended a final dividend of ₹1.30 per share. Fourth-quarter performance was particularly robust, with PAT rising 12.4% year-on-year to ₹1,106.10 million.
Key Highlights
Annual Revenue from operations grew to ₹31,857.62 million in FY26 from ₹30,903.69 million in FY25.
Net Profit for FY26 increased by 8.2% YoY to ₹5,431.39 million, resulting in an EPS of ₹10.88.
Board recommended a final dividend of ₹1.30 per equity share (13% of face value) for FY26.
Q4 FY26 PAT stood at ₹1,106.10 million, a 12.4% increase compared to ₹984.07 million in the same quarter last year.
Cash and cash equivalents at the end of the year nearly doubled to ₹675.29 million from ₹343.42 million.
👀 What to Watch
Investors should consider this a stable performance reflecting the company's resilience in the seasonal agro-chemical sector. The debt-free status and consistent dividend payout make it a strong long-term hold.
Sumitomo Chemical Q3 Revenue Dips 12% to ₹568 Cr; Margins Expand to 47.4%
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business and soft domestic demand. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% through a superior product mix and disciplined pricing. Net profit fell 13% YoY to ₹75.8 crore, weighed down by a one-time exceptional charge of ₹16.1 crore related to newly notified Labour Codes. The company provided clarity on its ₹160 crore capex projects, with commercialization expected between Q4 FY28 and Q2 FY29.
Key Highlights
Q3FY26 revenue fell 12% YoY to ₹568 crore, while 9MFY26 revenue grew 3% to ₹2,555 crore.
Gross margins improved to 47.4% in Q3 from 42.1% YoY, supported by the exit from the low-margin AND business (₹72 crore impact).
Net Profit for Q3 stood at ₹75.8 crore, impacted by a ₹16.1 crore one-time exceptional charge for Labour Code compliance.
Announced commercialization timelines for ₹150 crore Dahej project (Q2 FY29) and ₹10 crore Tarapur project (Q4 FY28).
Maintains a strong balance sheet with cash and cash equivalents of approximately ₹2,163 crore as of December 31, 2025.
👀 What to Watch
Investors should focus on the significant margin expansion and the company's transition toward high-margin patented molecules from its parent company. While short-term domestic demand remains soft, the strong cash position and upcoming capex provide a solid long-term growth outlook.
Sumitomo Chemical Q3 PAT Falls 13% to ₹76 Cr on One-time Charge; Margins Expand 522 bps
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% due to a favorable product mix and disciplined pricing. Net profit fell 13% to ₹75.8 crore, primarily impacted by a one-time exceptional charge of ₹16.1 crore related to new Labour Code provisions. The company also announced a strategic ₹150 crore capex for its Dahej site to manufacture patented molecules for its Japanese parent company.
Key Highlights
Q3 Revenue declined 12% YoY to ₹568 crore, impacted by a ₹72 crore revenue loss from discontinued low-margin business.
Gross Profit Margin improved to 47.4% from 42.1% YoY, while EBITDA margin rose to 17.5%.
Board approved ₹150 crore capex for a herbicide intermediate plant at Dahej for global supply to the parent company.
Net Profit of ₹75.8 crore was affected by a ₹16.1 crore one-time exceptional charge; excluding this, PBT remained stable.
Cash and cash equivalents stood at a robust ₹2,163 crore as of December 31, 2025.
👀 What to Watch
Investors should look past the headline PAT decline as it was driven by a one-time charge and the exit from low-margin segments. The significant margin expansion and the new capex for the parent company's patented molecules signal a positive long-term shift toward higher-value manufacturing.
Sumitomo Chemical India Files Q3 FY26 Results; Reports Zero Loan Defaults
Sumitomo Chemical India Limited has submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting concluded on January 27, 2026, confirming the approval of these results without any audit qualifications. The company reported zero deviations in the use of proceeds from public or preferential issues. Additionally, no defaults on loans or debt securities were reported for the period.
Key Highlights
Board approved unaudited standalone and consolidated financial results for Q3 and 9M ended Dec 31, 2025
Company confirmed zero outstanding defaults on loans and debt securities as of the reporting date
Reported zero deviations or variations in the utilization of proceeds from public or rights issues
The financial results were submitted with an unqualified audit opinion for the period ending December 2025
Board meeting for result approval was conducted between 12:12 P.M. and 01:51 P.M. on January 27, 2026
👀 What to Watch
Investors should examine the detailed Annexure I for specific revenue and margin trends to assess operational performance. The lack of audit qualifications and debt defaults indicates a stable regulatory and credit profile.
